No Data
No Data
Haitong International: Free circuit with long slopes and heavy snow, domestic market space is expected to open up
The Zhitong Finance App learned that Haitong International released a research report saying that compared with innovative domestic drugs to replace relatively mature oncology drugs, self-exempt drugs also have the advantage of a large market size (suitable for the domestic pricing environment for new drugs). The differences are that patients are widely distributed (channel coverage is required), are more chronic diseases, and there is competition for traditional drugs (requiring fast efficacy and high accessibility). Combined with the current market financing environment, although the self-defense target layout is still crowded, companies with good cash flow will be more likely to obtain excess profits. It is recommended to pay attention to Hengrui Pharmaceutical (600276.SH), Kangzhe Pharmaceutical (00867), Sansheng Guojian (688)
Repurchase Collection on April 24 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$82,6392 million
According to HKEx's April 25 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 1,285,200 common shares on April 23, involving an amount of HK$82,6392 million. The repurchase price per share ranged from HK$64.65 to HK$64.05. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 24, involving an amount of HK$597.95 million, with a repurchase price of HK$100.3 per share
Kangzhe Pharmaceutical (00867.HK) spent HK$7.3872 million to buy back 1.05 million shares on April 24
Gelonghui, April 24 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$7.3872 million to repurchase 1.05 million shares on April 24.
Kangzhe Pharmaceutical (00867.HK): The application for permission to market dexidolastat tablets in China has been accepted
Kangzhe Pharmaceutical (00867.HK) announced that the new drug marketing license application (NDA) for desidustat tablets (former name: dexidostat tablets) was accepted by the China National Drug Administration (NMPA) on April 22, 2024. The product is an innovative oral hypoxia-inducible factor-proline hydroxylase inhibitor (HIF-PHI), intended for the treatment of anemia in non-dialyzed adult patients with chronic kidney disease (CKD).
Repurchase Collection on April 17 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$226 million
According to HKEx's April 18 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.6 million common shares on April 16, involving an amount of HK$226 million. The repurchase price per share ranged from HK$63.05 to HK$62.25. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 17, involving an amount of HK$57.427,600. The repurchase price per share ranged from HK$96.65 to 94.9
Kangzhe Pharmaceutical (00867.HK) spent HK$7.423,800 to buy back 1.06 million shares on April 17
Gelonghui, April 17 | Kangzhe Pharmaceutical (00867.HK) announced that it spent HK$7.423,800 to buy back 1.06 million shares on April 17.
No Data